Literature DB >> 10897108

Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma.

T Nakashima1, J M Hudson, G L Clayman.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent paracrine angiogenic factor involved in angiogenesis. We determined whether antisense VEGF transfection can suppress angiogenic activity of a human squamous cell carcinoma of the head and neck (SCCHN) cell line.
METHODS: Human SCCHN cell lines were screened for VEGF secretion by ELISA. The highest VEGF secreting cell line was transfected with an antisense VEGF vector. Endothelial cell migration assays were performed using the conditioned medium from the transfected clones. Tumorigenicity assays of the transfectants in nude mice were also performed.
RESULTS: Antisense VEGF expression exhibited a 20-fold inhibition of VEGF secretion. The addition of conditioned medium from the antisense clones resulted in 50% reduction of endothelial migration. There was no effect on in vivo tumorigenicity.
CONCLUSIONS: Antisense VEGF transfection effectively down-regulated VEGF secretion from SCCHN cells that had high VEGF secretion. Targeting VEGF expression may be useful for suppressing angiogenesis in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897108     DOI: 10.1002/1097-0347(200008)22:5<483::aid-hed7>3.0.co;2-h

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  3 in total

1.  Angiogenic role for glycodelin in tumorigenesis.

Authors:  M Song; S Ramaswamy; S Ramachandran; L C Flowers; I R Horowitz; J A Rock; S Parthasarathy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

2.  Molecular approaches to sarcoma therapy.

Authors:  R J Olsen; S R Tarantolo; S H Hinrichs
Journal:  Sarcoma       Date:  2002

3.  Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.

Authors:  W Shi; D W Siemann
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.